🇺🇸 FDA
Patent

US 10982212

Conserved HBV and HCV sequences useful for gene silencing

granted A61KA61K31/713A61P

Quick answer

US patent 10982212 (Conserved HBV and HCV sequences useful for gene silencing) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/713, A61P, A61P31/14, A61P31/20